Liu M, Yang J, Wan L, et al. - Researchers undertook this retrospective study to examine the relationship between lymphocyte percentage (LY%), fibrinogen (FIB), fibrinogen-to-lymphocyte percentage ratio (FLR) and the tumor staging and the clinical result role among non-small cell lung cancer (NSCLC) patients undergoing chemotherapy or surgery combined with chemotherapy. This analysis involved 375 NSCLC patients and 201 healthy individuals. Significant difference in concentration levels of LY%, FIB, and FLR was found between stage III–IV group and stage I–II group, which implies a significant correlation of three biomarkers (LY%, FIB, and FLR) with tumor staging. An elevated death risk was observed in relation to pretreatment high FIB and FLR and low LY%. A superior clinical outcome was revealed in low FLR patients with chemotherapy or chemotherapy combined with surgery, relative to high FLR patients. Findings revealed that not only NSCLC staging could be predicted by FLR but also it was identified as an independent prognosis factor within NSCLC patients undergoing chemotherapy or chemotherapy combined with surgery.